Influence of Co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation

D. Cattaneo, S. Merlini, S. Zenoni, S. Baldelli, E. Gotti, G. Remuzzi, N. Perico

Research output: Contribution to journalArticle

Abstract

The pharmacokinetics of mycophenolic acid (MPA) - the active metabolite of mycophenolate mofetil (MMF) - is significantly influenced by co-medications. The impact of sirolimus on daily MPA exposure, however, has not been investigated so far. As a part of the study aimed at investigating the efficacy of Campath-1H induction therapy in a steroid-free regimen in kidney transplantation, MPA plasma levels were serially measured in 21 patients treated with low-dose sirolimus (SRL) or low-dose CsA both in addition to low-dose MMF over 12 months post-operatively. Full pharmacokinetic profiles were compared at month 6 and 12 post-surgery. Mean dose-adjusted MPA trough levels were 4.4-fold higher in patients on combined SRL and MMF than in those given CsA and MMF. Pharmacokinetic studies demonstrated that mean MPA Cmax and T max were comparable in the two groups, while mean MPA AUC 0-12 was higher in SRL than CsA treated patients. The pharmacokinetic profile of SRL- but not of CsA-group showed a second peak consistent with the enterohepatic recirculation of MPA. These findings suggest that SRL and CsA have different effects on MPA metabolism and/or excretion eventually affecting its immunosuppressive property and/or toxicity. CsA, but not SRL, inhibits MPA enterohepatic recirculation, reducing MPA daily exposure.

Original languageEnglish
Pages (from-to)2937-2944
Number of pages8
JournalAmerican Journal of Transplantation
Volume5
Issue number12
DOIs
Publication statusPublished - Dec 2005

Fingerprint

Mycophenolic Acid
Sirolimus
Kidney Transplantation
Cyclosporine
Pharmacokinetics
Immunosuppressive Agents

Keywords

  • Cyclosporine
  • Drug-drug interactions
  • Kidney transplantation
  • Mycophenolic acid
  • Pharmacokinetics
  • Sirolimus

ASJC Scopus subject areas

  • Immunology

Cite this

Influence of Co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation. / Cattaneo, D.; Merlini, S.; Zenoni, S.; Baldelli, S.; Gotti, E.; Remuzzi, G.; Perico, N.

In: American Journal of Transplantation, Vol. 5, No. 12, 12.2005, p. 2937-2944.

Research output: Contribution to journalArticle

@article{1b82736bcdd8417bbd412585bcc409fe,
title = "Influence of Co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation",
abstract = "The pharmacokinetics of mycophenolic acid (MPA) - the active metabolite of mycophenolate mofetil (MMF) - is significantly influenced by co-medications. The impact of sirolimus on daily MPA exposure, however, has not been investigated so far. As a part of the study aimed at investigating the efficacy of Campath-1H induction therapy in a steroid-free regimen in kidney transplantation, MPA plasma levels were serially measured in 21 patients treated with low-dose sirolimus (SRL) or low-dose CsA both in addition to low-dose MMF over 12 months post-operatively. Full pharmacokinetic profiles were compared at month 6 and 12 post-surgery. Mean dose-adjusted MPA trough levels were 4.4-fold higher in patients on combined SRL and MMF than in those given CsA and MMF. Pharmacokinetic studies demonstrated that mean MPA Cmax and T max were comparable in the two groups, while mean MPA AUC 0-12 was higher in SRL than CsA treated patients. The pharmacokinetic profile of SRL- but not of CsA-group showed a second peak consistent with the enterohepatic recirculation of MPA. These findings suggest that SRL and CsA have different effects on MPA metabolism and/or excretion eventually affecting its immunosuppressive property and/or toxicity. CsA, but not SRL, inhibits MPA enterohepatic recirculation, reducing MPA daily exposure.",
keywords = "Cyclosporine, Drug-drug interactions, Kidney transplantation, Mycophenolic acid, Pharmacokinetics, Sirolimus",
author = "D. Cattaneo and S. Merlini and S. Zenoni and S. Baldelli and E. Gotti and G. Remuzzi and N. Perico",
year = "2005",
month = "12",
doi = "10.1111/j.1600-6143.2005.01107.x",
language = "English",
volume = "5",
pages = "2937--2944",
journal = "American Journal of Transplantation",
issn = "1600-6135",
publisher = "Wiley-Blackwell",
number = "12",

}

TY - JOUR

T1 - Influence of Co-medication with sirolimus or cyclosporine on mycophenolic acid pharmacokinetics in kidney transplantation

AU - Cattaneo, D.

AU - Merlini, S.

AU - Zenoni, S.

AU - Baldelli, S.

AU - Gotti, E.

AU - Remuzzi, G.

AU - Perico, N.

PY - 2005/12

Y1 - 2005/12

N2 - The pharmacokinetics of mycophenolic acid (MPA) - the active metabolite of mycophenolate mofetil (MMF) - is significantly influenced by co-medications. The impact of sirolimus on daily MPA exposure, however, has not been investigated so far. As a part of the study aimed at investigating the efficacy of Campath-1H induction therapy in a steroid-free regimen in kidney transplantation, MPA plasma levels were serially measured in 21 patients treated with low-dose sirolimus (SRL) or low-dose CsA both in addition to low-dose MMF over 12 months post-operatively. Full pharmacokinetic profiles were compared at month 6 and 12 post-surgery. Mean dose-adjusted MPA trough levels were 4.4-fold higher in patients on combined SRL and MMF than in those given CsA and MMF. Pharmacokinetic studies demonstrated that mean MPA Cmax and T max were comparable in the two groups, while mean MPA AUC 0-12 was higher in SRL than CsA treated patients. The pharmacokinetic profile of SRL- but not of CsA-group showed a second peak consistent with the enterohepatic recirculation of MPA. These findings suggest that SRL and CsA have different effects on MPA metabolism and/or excretion eventually affecting its immunosuppressive property and/or toxicity. CsA, but not SRL, inhibits MPA enterohepatic recirculation, reducing MPA daily exposure.

AB - The pharmacokinetics of mycophenolic acid (MPA) - the active metabolite of mycophenolate mofetil (MMF) - is significantly influenced by co-medications. The impact of sirolimus on daily MPA exposure, however, has not been investigated so far. As a part of the study aimed at investigating the efficacy of Campath-1H induction therapy in a steroid-free regimen in kidney transplantation, MPA plasma levels were serially measured in 21 patients treated with low-dose sirolimus (SRL) or low-dose CsA both in addition to low-dose MMF over 12 months post-operatively. Full pharmacokinetic profiles were compared at month 6 and 12 post-surgery. Mean dose-adjusted MPA trough levels were 4.4-fold higher in patients on combined SRL and MMF than in those given CsA and MMF. Pharmacokinetic studies demonstrated that mean MPA Cmax and T max were comparable in the two groups, while mean MPA AUC 0-12 was higher in SRL than CsA treated patients. The pharmacokinetic profile of SRL- but not of CsA-group showed a second peak consistent with the enterohepatic recirculation of MPA. These findings suggest that SRL and CsA have different effects on MPA metabolism and/or excretion eventually affecting its immunosuppressive property and/or toxicity. CsA, but not SRL, inhibits MPA enterohepatic recirculation, reducing MPA daily exposure.

KW - Cyclosporine

KW - Drug-drug interactions

KW - Kidney transplantation

KW - Mycophenolic acid

KW - Pharmacokinetics

KW - Sirolimus

UR - http://www.scopus.com/inward/record.url?scp=33644824716&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33644824716&partnerID=8YFLogxK

U2 - 10.1111/j.1600-6143.2005.01107.x

DO - 10.1111/j.1600-6143.2005.01107.x

M3 - Article

C2 - 16303008

AN - SCOPUS:33644824716

VL - 5

SP - 2937

EP - 2944

JO - American Journal of Transplantation

JF - American Journal of Transplantation

SN - 1600-6135

IS - 12

ER -